Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-30

Study Completion Date

2010-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to determine if treatment with pantoprazole 40 mg daily versus a placebo improves sleep quality in patients with gastroesophageal reflux disease (GERD). Another purpose is to determine if treatment with pantoprazole 40 mg once daily versus a placebo improves sleep outcomes in patients with gastroesophageal reflux disease using spectral analysis of sleep electroencephalogram (EEG).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders

NCT00830115

Sleep Disorders Non-Erosive Reflux Disease Gastroesophageal Reflux Disease

COMPLETED

Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US

NCT00660660

Gastroesophageal Reflux Disease

COMPLETED PHASE4

Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)

NCT00246909

Gastroesophageal Reflux

COMPLETED PHASE4

Predictors of Proton Pump Inhibitor Response in Gastroesophageal Reflux Disease Patients

NCT01797939

Erosive Reflux Disease Non-erosive Reflux Disease Functional Heartburn

COMPLETED

Gastroesophageal Reflux Disease (GERD)/Nighttime Heartburn and Driving Performance

NCT01079884

GERD

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It appears that the presence of intraesophageal stimuli alone may not be sufficient to elicit symptoms of heartburn. Most acid reflux events (\>80%-90%) do not reach conscious level and thus are not perceived.\[3\] It is yet to be determined what factors enhance our perception of esophageal stimuli and may help to elevate them to the conscious level. In recent years, central and peripheral factors that may enhance our perception of intraesophageal stimuli have been evaluated. Intraduodenal fat infusion was shown to enhance perception of intraesophageal acid in patients with GERD.\[4\] This study suggested that fat is an important modulator of postprandial GERD symptoms. Central factors, such as stress and psychological comorbidity, also appear to have an important role in symptom generation in patients with GERD, regardless if esophageal inflammation is present or absent.\[5-8\] Thus, by modulating brain-gut interactions, perception of pathological and probably physiological events in the esophagus of patients with GERD may be altered.

Poor sleep is a central factor that may enhance perception of intraesophageal stimuli and thus elevate them to the conscious level. Several studies have demonstrated that patients with fibromyalgia or irritable bowel syndrome report increased symptoms due to sleep abnormalities.\[9, 10\] Similar reports in patients with GERD are not available. A subset of patients with GERD experience nocturnal heartburn that may awaken them during the night. In others, despite lack of nocturnal symptoms, sleep abnormalities may occur due to acid reflux events. In both cases, GERD leads to poor sleep, and that in turn may enhance perception of intraesophageal stimuli, leading to reports of increased frequency and severity of perceived GERD symptoms. Thus, poor sleep may be a crucial factor in symptom generation and exacerbation of patients with GERD.

Recently, we have used a novel technique, power spectral analysis of the sleep electroencephalogram (EEG), to assess patients with heartburn and erosive esophagitis and those with heartburn but without erosive esophagitis.\[11\] We were able to show that among heartburn patients with GERD, EEG spectral power during sleep is shifted towards higher frequencies as compared to heartburn patients without GERD despite similar sleep architecture.

Several recent therapeutic trials in GERD patients have failed to demonstrate improvement in polysomnographic studies despite improvement in GERD-related symptoms and subjective reports of sleep quality.\[12\] Spectral analysis of the sleep EEG might be a more sensitive tool than polysomnographic study in assessing objective improvement of sleep in patients receiving antireflux treatment.

In summary, sleep disturbances in patients with GERD are poorly recognized and rarely elicited during clinic visits despite their significant impact on patients' quality of life and probably perception of disease severity. Several studies have demonstrated improvement of subjective reports of sleep quality in patients with GERD receiving antireflux treatment. However, the effect of potent antireflux therapy on objective sleep parameters has yet to be demonstrated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroesophageal Reflux Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pantoprazole

40 mg once daily for four weeks improves sleep quality in patients with GERD

Group Type ACTIVE_COMPARATOR

Pantoprazole

Intervention Type DRUG

40 mg once daily for 4 weeks

Pantoprazole

Intervention Type DRUG

40 mg once daily improves sleep quality in patients with GERD.

placebo

To determine if treatment with pantoprazole 40 mg once daily vs placebo improves sleep outcome in patients with GERD.

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

40 mg once daily for 4 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pantoprazole

40 mg once daily for 4 weeks

Intervention Type DRUG

Pantoprazole

40 mg once daily improves sleep quality in patients with GERD.

Intervention Type DRUG

placebo

40 mg once daily for 4 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Protonix PPI Protonix PPI sugar pill

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 to 80 yrs of age
* 2 to 3 episodes of GERD/week
* erosive esophagitis or abnormal 24 hr pH
* able to read and understand, complete questionnaires

Exclusion Criteria

* barrett's esophagus or peptic stricture on endoscopy
* normal EGD and normal 24 hour pH
* previous upper GI surgery
* comorbidity (cardiovascular, respiratory, renal, hepatic)
* use of narcotics or pain medication on regular basis
* insomnia, shift work sleep disorder, sleep apnea, restless leg syndrome
* diabetes, scleroderma or neuromuscular disorders

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes